Efficacy and safety of platelet-rich plasma as an adjunct therapy to split thickness skin graft in burn patients with granulating raw wounds: a prospective, randomized, double-blind study-study protocol.

 0 Người đánh giá. Xếp hạng trung bình 0

Tác giả: Bhavani Shankara Bagepally, Susmita Behera, Jerin Jose Cherian, Gunjan Kumar, Vijay Kumar, Smita Mahapatra, Madan Mohan Majhi, Biswajit Mishra, Aparna Mukherjee, P Nellaiappar, Sudipto Roy, Binay Bhusan Sahoo, Arindam Sarkar, S ShoganRaj

Ngôn ngữ: eng

Ký hiệu phân loại:

Thông tin xuất bản: England : Trials , 2025

Mô tả vật lý:

Bộ sưu tập: NCBI

ID: 696925

 BACKGROUND: Burn wounds are commonly encountered in clinical settings and the management aims at the prevention of mortality and morbidity due to disability. The platelet-rich plasma (PRP) is blood-derived biomaterial that is enriched with growth factors and cytokines that facilitate wound healing. The PRP has proven its efficacy in various other wounds, but its role in post-burn raw areas and graft take has not been validated. This proposed multicentre randomized controlled trial aims to evaluate the efficacy and safety of platelet-rich plasma as an adjunct therapy to split-thickness skin graft in burn patients with granulating raw wounds. METHOD/DESIGN: This trial is an investigator-initiated, double-blind multicentre, randomized controlled parallel arm trial alongside trial cost-effectiveness analysis. Granulating deep second-degree and third-degree burns affecting 3-20% of total body surface area (TBSA) at 10-14th post-burn day will be included in the study. A total of 550 patients (275 in each group) will be randomized to receive either standard skin graft or allogenic PRP with skin graft treatment. The primary endpoint will be the mean percentage of graft-take on the 14th postoperative day. The result will be analyzed by two independent assessors who are blinded to the study. Secondary endpoints include (a) time taken for complete wound healing
  (b) frequency of adverse events
  (c) follow-up with scar index at 3 months, 6 months, and 1 year using the Patient and Observer Scar Assessment Scale (POSAS) score
  (d) cost-effectiveness analysis of the intervention compared to the comparator
  and (e) to estimate in a subset of participants the association between growth factor levels (PDGF BB and TGF ß-1) of activated PRP and clinical response. DISCUSSION: The proposed trial will be expected to verify the efficacy and safety of PRP for split-thickness skin graft (STSG) in deep second-degree or third-degree granulating wounds of burn patients based on the outcome of the study.
Tạo bộ sưu tập với mã QR

THƯ VIỆN - TRƯỜNG ĐẠI HỌC CÔNG NGHỆ TP.HCM

ĐT: (028) 36225755 | Email: tt.thuvien@hutech.edu.vn

Copyright @2024 THƯ VIỆN HUTECH